During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

The optimization of upstream and downstream processes for production of recombinant
adeno-associated virus (rAAV) with consistent quality depends on the ability to rapidly …

There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

Monoclonal antibodies play an increasingly important role for the development of new drugs
across multiple therapy areas. The term 'developability'encompasses the feasibility of …

There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which
spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far …

Accelerated development of new therapeutics in an increasingly competitive landscape
requires the use of high throughput analytical platforms. In addition, the complexity of novel …

Monoclonal antibodies (mAbs) and antibody–drug conjugates (ADCs) are two of the most
important therapeutic drug classes that require extensive characterization, whereas their …

Forced degradation studies have become integral to the development of recombinant
monoclonal antibody therapeutics by serving a variety of objectives from early stage …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …